Eisai's BAN2401 prototype Alzheimer's drug gets a rocky phase II reception, risks joining other failed attempts to tackle neurodegenerative disease

November 02, 2018 | Case Study

BAN2401 is a prototype Alzheimer's drug that originally traces back to BioArctic Neuroscience, a Swedish biopharmaceutical company. Japan's Eisai licensed the drug's approach from BioArctic and is now working together with Boston-based Biogen for the joint development of BAN2401. The drug itself is a therapeutic antibody that binds to large, soluble amyloid beta protofibrils (amyloid beta is the main component of the amyloid plaques that are found in the brains of Alzheimer's patients). The developers of the drug hope that its initial beneficial effects – shown in mice to reduce the toxicity of amyloid beta protofibrils and to protect neural cells – will also be evident in the humanized version of the antibody, which is being studied now via clinical trials.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978